Background: Australia legalizes psychedelic therapies for treating specific mental health conditions

Australia has made history by becoming the first country to officially legalize the use of psychedelics to treat specific mental health conditions. As of July 1, licensed psychiatrists are authorized to prescribe MDMA for post-traumatic stress disorder (PTSD) and psilocybin, the active ingredient in so-called “magic mushrooms,” for depression that is resistant to prescription drugs and derivatives.

In February this year, Australia’s Therapeutic Goods Administration (TGA) made the decision to move MDMA and psilocybin from the strictest category of prohibited substances to the category of controlled drugs, but only for medical use.

Legal norms

However, the use of these psychedelics will not be free or completely indiscriminate. They will mainly be offered to patients who have not responded to other treatments, and doctors will only be able to prescribe them if the benefits outweigh the risks. Each case will be treated individually.

Additionally, patients will not be allowed to take these medications at home, even if prescribed and under the supervision of mental health professionals. They will be used as part of a psychedelic-assisted therapy, which will involve sessions supervised by trained professionals.

(Image: Mikhail Nilov/ Pexels)

While the efficacy of these treatments has yet to be established, growing evidence suggests that psychedelics have promising potential for treating certain mental health conditions. Clinical data collected in Australia will contribute to the growing body of evidence and help determine how best to use these medications.

The decision to authorise the medical use of psychedelics was widely welcomed by scientists in Australia when it was announced by the TGA in February 2023. However, some experts stressed the importance of exploring this new frontier with great caution and responsibility.

Kim Felmingham, clinical psychologist and director of the Centre for Brain and Mental Health Research at the University of Melbourne, explains:

“While MDMA-assisted therapy for PTSD is a promising and exciting development, rigorous research is needed to understand the underlying mechanisms of this therapy. This will allow us to determine which therapeutic approach works best for each individual with PTSD. No PTSD treatment is a silver bullet that works for everyone, and MDMA is no exception. Further research in this field will help us optimize our healthcare resources, direct people to the most effective treatments, and improve access to care for those living with PTSD,” said the professor.